Tegretol 200 mg Νορβηγία - Νορβηγικά - Statens legemiddelverk

tegretol 200 mg

novartis norge (2) - karbamazepin - tablett - 200 mg

Tegretol 20 mg/ ml Νορβηγία - Νορβηγικά - Statens legemiddelverk

tegretol 20 mg/ ml

novartis norge (2) - karbamazepin - mikstur, suspensjon - 20 mg/ ml

Tegretol 100 mg Νορβηγία - Νορβηγικά - Statens legemiddelverk

tegretol 100 mg

novartis norge (2) - karbamazepin - tablett - 100 mg

Tegretol Retard 400 mg Νορβηγία - Νορβηγικά - Statens legemiddelverk

tegretol retard 400 mg

novartis norge (2) - karbamazepin - depottablett - 400 mg

Tegretol Retard 200 mg Νορβηγία - Νορβηγικά - Statens legemiddelverk

tegretol retard 200 mg

novartis norge (2) - karbamazepin - depottablett - 200 mg

Trimonil Retard 300 mg Νορβηγία - Νορβηγικά - Statens legemiddelverk

trimonil retard 300 mg

desitin arzneimittel gmbh - karbamazepin - depottablett - 300 mg

Trimonil Retard 150 mg Νορβηγία - Νορβηγικά - Statens legemiddelverk

trimonil retard 150 mg

desitin arzneimittel gmbh - karbamazepin - depottablett - 150 mg

Trimonil Retard 600 mg Νορβηγία - Νορβηγικά - Statens legemiddelverk

trimonil retard 600 mg

desitin arzneimittel gmbh - karbamazepin - depottablett - 600 mg

Flebogamma DIF (previously Flebogammadif) Ευρωπαϊκή Ένωση - Νορβηγικά - EMA (European Medicines Agency)

flebogamma dif (previously flebogammadif)

instituto grifols s.a. - humant normalt immunglobulin - mucocutaneous lymph node syndrome; guillain-barre syndrome; bone marrow transplantation; purpura, thrombocytopenic, idiopathic; immunologic deficiency syndromes - immune sera og immunglobuliner, - replacement therapy in adults, children and adolescents (0-18 years) in: , primary immunodeficiency syndromes with impaired antibody production;, hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic luekaemia, in whom prophylactic antibiotics have failed;, hypogammaglobulinaemia and recurrent bacterial infections in plateau-phase-multiple-myeloma patients who failed to respond to pneumococcal immunisation;, hypogammaglobulinaemia in patients after allogenic haematopoietic-stem-cell transplantation (hsct);, congenital aids with recurrent bacterial infections. , immunomodulation in adults, children and adolescents (0-18 years) in: , primary immune thrombocytopenia (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count;, guillain barré syndrome;, kawasaki disease.

Raplixa Ευρωπαϊκή Ένωση - Νορβηγικά - EMA (European Medicines Agency)

raplixa

mallinckrodt pharmaceuticals ireland limited - human fibrinogen, human trombin - hemostase, kirurgisk - antihemoragika - støttende behandling der standard kirurgiske teknikker er utilstrekkelige for forbedring av hemostase. raplixa må brukes i kombinasjon med en godkjent gelatin svamp. raplixa er indisert hos voksne over 18 år.